文献速递肝病消化道肿瘤与早癌

肝硬化和年龄是原发性硬化性胆管炎患者肝细胞癌风险的关键决定因素:一项多中心纵向队列研究

Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
PubMed 文献 · Hepatology · 2025-04-16

本研究在12家大学医院的国际PSC登记协作组中纵向随访3071例原发性硬化性胆管炎患者共38387人年,39例发生肝细胞癌,平均距诊断16.4年。肝细胞癌与肝硬化(IRR 10.8,95%CI 5.7-20.5)和年龄(IRR 1.05,95%CI 1.03-1.08)相关;无肝硬化者风险低,50岁以下尤其低。结论认为PSC患者的肝细胞癌监测可基于年龄和肝硬化状态进行定制。

要点

  • 3071例PSC患者随访38387人年,39例发生肝细胞癌,平均距PSC诊断16.4年。
  • 肝细胞癌与肝硬化(IRR 10.8,95%CI 5.7-20.5)和年龄(IRR 1.05,95%CI 1.03-1.08)相关。
  • 无肝硬化者肝细胞癌风险低,50岁以下尤其低;监测可基于年龄和肝硬化状态定制。

核心结论

  • 无肝硬化的原发性硬化性胆管炎患者肝细胞癌相对罕见,50岁以下者尤其如此。
  • 研究结果提示PSC患者的肝细胞癌监测可基于年龄和肝硬化状态进行定制。

研究设计与样本

  • 多中心纵向队列研究,纳入国际PSC登记协作组12家大学医院中特征明确的PSC患者3071例,随访共38387人年。
  • 随访自PSC诊断至死亡、肝移植、诊断肝胆恶性肿瘤或2024年2月。
  • 采用泊松回归计算总人群及不同年龄和肝硬化状态亚组的肝细胞癌发病率比。

主要发现

  • 39例在PSC诊断后平均16.4年(标准差±10.7)发生肝细胞癌,其中26例(66.7%)在肝细胞癌前已诊断肝硬化。
  • 肝细胞癌诊断时平均年龄55.6岁(标准差±13.1岁),28例(71.8%)为男性。
  • 肝细胞癌与肝硬化相关(IRR 10.8,95%CI 5.7-20.5),与年龄相关(IRR 1.05,95%CI 1.03-1.08)。
  • 50岁时肝硬化男性发病率为0.81,肝硬化女性为0.47。
  • 无肝硬化者无论男女及所有年龄组风险均低。

关键数值与推荐

  • 肝细胞癌与肝硬化的IRR为10.8(95%CI 5.7-20.5)。
  • 肝细胞癌与年龄的IRR为1.05(95%CI 1.03-1.08)。
  • 50岁时肝硬化男性肝细胞癌发病率为0.81,肝硬化女性为0.47。

临床怎么用

  • 作者认为PSC患者的肝细胞癌监测可基于年龄和肝硬化状态进行定制。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The risk of HCC in primary sclerosing cholangitis (PSC) is unclear. Studies indicate a low risk for HCC, questioning the rationale for current HCC surveillance guidelines. This study explores the risk of HCC in a longitudinal multicenter cohort with over 3000 PSC subjects. APPROACH AND RESULTS: Subjects with well-characterized PSC (n=3071) were followed at 12 university hospitals within the International PSC Registry (IPSCR) collaboration for a total of 38,387 person-years. Incident HCC was registered. Subjects were followed from PSC diagnosis until death, liver transplantation, diagnosis of hepatobiliary malignancy, or February 2024. Poisson regression was used to calculate incidence rate ratios for HCC for the total population and for subgroups of different ages and cirrhosis status. Thirty-nine subjects developed HCC after a mean time of 16.4 years (SD ±10.7) from PSC diagnosis. In 26 (66.7%) of HCC cases, cirrhosis was diagnosed before HCC. The mean age at HCC diagnosis was 55.6 years (±SD13.1 years), and 28 (71.8%) were male. HCC was associated with cirrhosis (IRR: 10.8, 95% CI: 5.7-20.5) and age (IRR 1.05, 95% CI: 1.03-1.08). At the age of 50, the incidence rate was 0.81 and 0.47 for cirrhotic men and women, respectively. For non-cirrhotic subjects, the risk was low for both men and women and all age groups. CONCLUSION: HCC is relatively rare in patients with primary sclerosing cholangitis who do not have cirrhosis, especially in those under the age of 50. Our findings indicate that HCC monitoring for patients with PSC can be tailored based on their age and cirrhosis status.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Holmer M, Ingre M, Färkkilä M, et al. Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study. Hepatology. 2025. PMID: 40238209. doi:10.1097/HEP.0000000000001351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。